Show simple item record

dc.contributor.authorZakerzadeh, E
dc.contributor.authorAlizadeh, E
dc.contributor.authorKafil, HS
dc.contributor.authorHassanzadeh, AM
dc.contributor.authorSalehi, R
dc.contributor.authorMahkam, M
dc.date.accessioned2018-08-26T07:21:20Z
dc.date.available2018-08-26T07:21:20Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/46095
dc.description.abstractHere a novel antibacterial nanocomposite was developed for combination cancer therapy. The synthesized nanocarrier was characterized by FTIR, H-1 NMR, thermogravimetric analysis (TGA), and FESEM-EDX. Its antibacterial activity was assessed by determining minimum inhibitory concentration (MIC) values. Doxorubicin (DOX) and methotrexate (MTX) conjugation with nanocarrier sustained the release of both drugs with apparent pH-triggered manner. Co-administration of DOX with MTX leads to an efficient anticancer performance to MCF7 cell lines verified by qRT-PCR and MTT assay tests. It was concluded that this novel drug delivery vehicle makes antibacterial and anticancer therapeutic processes proceed spontaneously, representing more efficient drug delivery system in nanomedicine.
dc.language.isoEnglish
dc.relation.ispartofARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
dc.subjectAntibacterial polymers
dc.subjectcombination therapy
dc.subjectdual anticancer drug
dc.subjectsustained release
dc.subjectstimuli responsive
dc.subjectnanocomposite
dc.titleNovel antibacterial polymeric nanocomposite for smart co-delivery of anticancer drugs
dc.typeArticle
dc.citation.volume45
dc.citation.issue8
dc.citation.spage1509
dc.citation.epage1520
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.1080/21691401.2016.1260576


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record